Ann: Positive Results from IHL-675A (ARDS) in vitro Study, page-67

Correct, at least IMO.

The in-vitro results demonstrate that both HCQ and CBD inhibit cytokine production. In fact, at the highest concentrations tested (which are still well below what is deemed to be a “safe” dose) cytokine production was completely inhibited.

The next step is to identify the optimal combination of CBD and HCQ for the IHL-675A fixed dose product. This is not creating the wheel, it’s testing what has been proven to work, but now in combination.

The idea is to ascertain the minimum dose of CBD and HCQ in combination while still maintaining efficacy. This will be assessed both in-vitro and in-vivo.

At that stage IHL would submit an application for FDA approval using the current Emergency Use Authorization provisions. And, they would also be able to potentially sell a manufactured product under the Special Access Scheme.

Short term momentum punters will make a few bucks here and there and then lose it all again when the market turns. I’ve seen it all before.

Meanwhile IHL gets closer to an actual drug discovery and serious money like Glenn Poswell (ex-Packer fund manager) and another entity acquires 50 million shares. Why? Because a genuine drug discovery will put this stock into orbit and they know it...